medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2009, Number 5

<< Back Next >>

Rev Invest Clin 2009; 61 (5)

Factors associated with Clostridium difficile disease in a tertiary-care medical institution in Mexico: a case-control study

Camacho-Ortiz A, Galindo-Fraga A, Rancel-Cordero A, Macías AE, Lamothe-Molina P, Ponce de León-Garduño A, Sifuentes-Osornio J

Language: Spanish
References: 23
Page: 371-377
PDF size: 73.19 Kb.


ABSTRACT

Introduction. Clostridium difficile-associated disease (CDAD) has been clearly associated with the use of broad-spectrum antibiotics worldwide. However, information about CDAD is scarce in Mexico and Latin America. Material and methods. We studied clinical characteristics, associated factors and outcomes of all cases of CDAD diagnosed by toxin A fecal detection in a tertiary care hospital in Mexico City from 2003 to 2007. Cases were paired with controls by date of hospital discharge. Results. A total of 3170 tests were performed; we evaluated 113 cases and 226 controls, with an incidence of 5.04 cases x 1000 hospital discharges during the study period. There was no difference in gender or primary diagnosis. After multivariate analysis, we found as significant risks the following: use of H2 blockers (OR 21.73, 95% CI 7.14-66.67, p ‹ 0.001), age ‹ 65 y (OR 10.21, IC95% 2.74-38.00, p ‹ 0.001), prior hospitalization within 12 weeks of diagnosis (OR 4.39, IC95% 1.81-40.64, p ‹ 0.001), prior use of cephalosporins (OR 3.41, CI 95% 1.56-7.46, p = 0.002), and fluoroquinolones (OR 3.11, IC95% 1.12-8.62, p = 0.029), stay at the intensive care unit (ICU) (OR 2.76, IC95% 1.38-5.49, p = 0.004); and, extended hospital stay (OR 1.10, IC95% 1.05-1.16, p ‹ 0.001) or antimicrobial use before diagnosis (OR 1.05, IC95% 1.01-1.09, p = 0.010). We described an outbreak of 12 cases occurred in August of 2005 (29.5 cases per 1,000 discharges). We also observed a higher seasonal incidence of disease during the summer in the study period. Conclusions. The use of H2 blockers, age ‹ 65 years, prior hospitalization or earlier use of cephalosporins or fluoroquinolones, as well as stay at the ICU were independent risk factor for CDAD.


REFERENCES

  1. Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 2002; 346: 334-9.

  2. Bartlett JG, Onderdonk AB, Cisneros RL, Kasper DL. Clindamycin- associated colitis due to a toxin-producing species of Clostridium in hamsters. J Infect Dis 1977; 136: 701-5.

  3. Kyne L, Hamel MB, Polavaram R, Kelly CP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 2002; 34: 346-53.

  4. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection patients discharged from short-stay hospitals, 1996– 2003. Emerg Infect Dis 2006; 12: 409-15.

  5. Muto CA, Blank MK, Marsh JW, Vergis EN, O’Leary MM, Shutt KA, et al. Control of an outbreak of infection with the hypervirulent Clostridium difficile BI strain in a university hospital using a comprehensive bundle approach. Clin Infect Dis 2007; 45: 1266-73.

  6. Pepin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 2005; 173: 1037-42.

  7. Morgan OW, Rodrigues B, Elston T, Verlander NQ, Brown DFJ, Brazier J, et al. Clinical severity of Clostridium difficile PCR ribotype 027: A case-case study. PLoS ONE 3(3):e1812. doi:10.1371/journal.pone.0001812.

  8. Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, et al. A predominantly clonal multi-institutional out break of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353: 2442-9.

  9. Fernandez-Canigia L, Nazar J, Arce M, Dadamio J, Smayevsky J, Bianchini H. Clostridium difficile diarrhea: frequency of detection in a medical center in Buenos Aires, Argentina. Rev Argent Microbiol 2001; 33: 101-7.

  10. Marcon AP, Gamba MA, Vianna LA. Nosocomial diarrhea in the intensive care unit. Braz J Infect Dis 2006; 10: 384-9.

  11. McDonald LC, Coignard B, Dubberke E, Song X, Horan T, Kutty PK, Ad Hoc Clostridium difficile Surveillance Working Group. Recommendations for surveillance of Clostridium difficile- associated disease. Infect Control Hosp Epidemiol 2007; 28: 140-5.

  12. Lipson SM, Tortora G, Tempone A, Fedorko DP, Spitzer ED. Rapid detection of Clostridium difficile in stool using the VIDAS R C. difficile Toxin A II assay. Diagn Microbiol Infect Dis 2003; 45: 117-21.

  13. Chavez-Tapia NC, Tellez-Avila FI, Garcia-Leiva J, Valdovinos MA. Use and overuse of proton pump inhibitors in cirrhotic patients. Med Sci Monit 2008; 14: 468-72.

  14. Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acidsuppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005; 294: 2989-95.

  15. Sanchez TH, Brooks JT, Sullivan PS, Juhasz M, Mintz E, Adult/Adolescent Spectrum of HIV Disease Study Group. Bacterial diarrhea in persons with HIV infection, United States, 1992-2002. Clin Infect Dis 2005; 41: 1621-7.

  16. Gardilcic M, Fica A, Chang M, Llanos C, Luzoro A. Diarrea asociada a Clostridium difficile en un hospital de adultos. Estudio descriptivo. Rev Chil Infect 2000; 17: 307-12.

  17. Wilcox MH, Mooney L, Bendall R, Settle CD, Fawley WN. A case-control study of community-associated Clostridium difficile infection. J Antimicrob Chemother 2008; 62: 388-96.

  18. Ponce de León S, Rangel-Frausto MS, Elías-López JI, Romero- Oliveros C, Huertas-Jiménez M. Infecciones nosocomiales: tendencias seculares de un programa de control en México. Salud Pública Mex 1999; 41(Suppl. 1): S5-S11.

  19. Nakajima H, Nakagomi T, Kamisawa T, Sakaki N, Muramoto K, Mikami T, et al. Winter seasonality and rotavirus diarrhoea in adults. Lancet 2001; 357: 1950.

  20. McFarland LV, Clarridge JE, Beneda HW, Raugi GJ. Fluoroquinolone use and risk factors for Clostridium difficile-associated disease within a Veterans Administration health care system. Clin Infect Dis 2007; 45: 1141-51.

  21. Price MF, Dao-Tran T, Garey KW, Graham G, Gentry LO, Dhungana L, et al. Epidemiology and incidence of Clostridium difficile-associated diarrhoea diagnosed upon admission to a university hospital. J Hosp Infect 2007; 65: 42-6.

  22. Kato H, Kato N, Watanabe K, Iwai N, Nakamura H, Yamamoto T, et al. Identification of toxin A-negative, toxin B-positive Clostridium difficile by PCR. J Clin Microbiol 1998; 36: 2178-82.

  23. Zilberberg MD, Shorr AF, Kollef MH. Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000-2005. Emerg Infect Dis 2008; 14: 929-31.




2020     |     www.medigraphic.com